The signal transduction modulator Rgs9-2 (Regulator of G protein signaling 9-2) plays a key role in dopaminergic and opioidergic transmission in the striatum. Rgs9-2 is a potent modulator of opiate reward and analgesia, but its role in chronic pain remains unknown. Here, we use the spared nerve injury model (SNI), to evaluate the influence of Rgs9-2 in sensory symptoms, as well as in anxiety and depression-like behaviors observed under neuropathic pain conditions. Our data demonstrate that knockout of the Rgs9 gene reduces the intensity of thermal hyperalgesia and mechanical allodynia the first few days after nerve injury. This small, but significant effect is only observed at early time points after nerve injury, whereas after the first week of SNI, Rgs9 knockout (Rgs9KO) and Rgs9 wildtype (Rgs9WT) mice show similar levels of mechanical allodynia and thermal hyperalgesia. Furthermore, Rgs9-2 deletion exacerbates anxiety and depression like behaviors several weeks after the emergence of the neuropathic pain symptoms. Our findings also reveal a temporal and regional regulation of Rgs9-2 protein expression by neuropathic pain, as Rgs9-2 levels are reduced in the spinal cord a few days after nerve injury, whereas decreased Rgs9-2 levels in the Nucleus Accumbens (NAc) are only observed several weeks after nerve injury. Thus, adaptations in Rgs9-2 activity in the spinal cord and in the NAc may contribute to sensory and affective components of neuropathic pain.
Introduction
Regulator of G protein signaling 9-2 (Rgs9-2) is a striatal enriched modulator of GPCR signal transduction (Hollinger & Hepler, 2002) . Rgs9-2 controls the signaling amplitude and duration of several GPCRs in the dorsal and ventral striatum, including dopamine and mu opioid receptors (Kimple, Bosch, Giguère, & Siderovski, 2011; Traynor, Terzi, Caldarone, & Zachariou, 2009 ). Rgs9-2 protein exerts its modulatory actions by binding to activated Ga subunits and accelerating their GTPase activity. Rgs9-2 also prevents Ga effector activation (Kimple et al., 2011) . The protein is expressed at very high levels in the striatum and at moderate to low abundance in the dorsal horn of the spinal cord. Rgs9-2 immunoreactivity is not detected in the dorsal root ganglia (Gold, Ni, Dohlman, & Nestler, 1997; Psigfogeorgou et al., 2011; Rahman et al., 2003) . Studies from various groups reveal a potent modulatory role of Rgs9-2 in drug addiction, opiate dependence and analgesia (Traynor et al., 2009 ). In addition, Rgs9-2 regulates the actions of antipsychotic and anti-Parkinsonian agents (Gold et al., 2007; Traynor et al., 2009 ). The mechanism of Rgs9-2 action involves the formation of complexes with several signal transduction and adaptor molecules. Interactions with these partner proteins determine the localization and stability of Rgs9-2. In particular, Rgs9-2 interacts with the adaptor molecule R7BP (Anderson, Semenov, Song, & Martemyanov, 2007; Martemyanov, Yoo, Skiba, & Arshavsky, 2005) which targets the protein near the cell membrane, whereas Rgs9-2 association with the Gb5 subunit confers stability (Kimple et al., 2011; Masuho, Wakasugi-Masuho, Posokhova, Patton, & Martemyanov, 2011) . Recent studies from our group demonstrated that Rgs9-2 plays either a positive or a negative modulatory role in mu opioid receptor (MOR) signaling, that is agonist dependent (Psifogeorgou et al., 2007) . Our more recent work also demonstrated that increased Rgs9-2 activity in the nucleus accumbens modulates opiate reward as well as opiate analgesia and tolerance (Gaspari et al., 2014) .
Rgs9-2 expression in CNS regions associated with mood disorders (NAc) and nociceptive transmission (spinal cord), led us to
